Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1/-2 analysis.

Front Allergy · 2026 · PMC13002596 · PMID 41868651

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

In the Phase III ANCHOR-1/-2 trials in patients with CRSwNP, depemokimab led to a nominally significant reduction vs. placebo in total endoscopic nasal polyps score [−0.7 points; 95% confidence interval (CI): −0.9, −0.4] and nasal obstruction verbal response score (-0.24 points; 95% CI: −0.39, −0.08).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.